研究人员将AASLD使用 DELFI 平台展示概念验证肝癌检测数据

StephenW

研究人员将在 AASLD The Liver Meeting® 2022 上使用 DELFI 平台展示概念验证肝癌检测数据

新闻提供者
德尔菲诊断

美国东部时间 2022 年 10 月 27 日 11:00
分享这篇文章

巴尔的摩和加利福尼亚州帕洛阿尔托，2022 年 10 月 27 日 /美通社/ -- 使用 DELFI 平台的研究人员将介绍新的数据证明了其在美国肝病研究协会年会 2022 年肝脏会议上准确检测高风险和平均风险个体肝癌的能力。
研究人员将在 AASLD The Liver Meeting® 2022 上使用 DELFI 平台展示概念验证肝癌检测数据
研究人员将在 AASLD The Liver Meeting® 2022 上使用 DELFI 平台展示概念验证肝癌检测数据

肝癌是美国第六大癌症杀手，也是全世界癌症相关死亡的第三大原因。在全球范围内，由于脂肪肝疾病、肝硬化和慢性病毒性肝炎感染的增加，超过 3.5 亿人的高危人群正在增长。与此同时，尽管长期以来一直建议筛查高危患者，但美国和全球的筛查率仍低于 20%。

研究人员将展示初步研究结果，表明其平台可以准确且经济高效地将肝细胞癌 (HCC) 患者与非癌症患者区分开来，即使他们患有其他合并症。

“肝癌是增长最快的癌症杀手，预计到 2035 年将成为美国癌症死亡的第三大原因。这令人兴奋地证明了 Delfi 平台解决日益严重的公共卫生问题的潜力，”Peter B 说. 巴赫，德尔菲的首席医疗官。

口头报告详情：
用于检测肝癌的无细胞 DNA 片段组
作者：Zachariah H. Foda 等。人
会议：HCC 风险分层和监测的新方法
日期：2022 年 11 月 7 日，星期一
时间：美国东部标准时间上午 9:00 - 10:30
关于 Delfi 诊断

Delfi 正在开发一种新的液体活检测试，用于基于改变的全基因组片段化谱进行早期检测，也称为“片段组”，代表癌细胞中 DNA 的异常包装。通过应用先进的机器学习算法，可以以非常低的测序成本检测到这些片段模式。 Delfi（“早期拦截片段的 DNA 评估”）正在使用该技术开发高度敏感和特异性的癌症检测分析，旨在广泛且具有成本效益的分发和采用。

消息来源 Delfi 诊断

StephenW

Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022

News provided by
Delfi Diagnostics

Oct 27, 2022, 11:00 ET
Share this article

BALTIMORE and PALO ALTO, Calif., Oct. 27, 2022 /PRNewswire/ -- Researchers using the DELFI platform, a technology for a new class of high performance, accessible liquid biopsy tests being commercialized by Delfi Diagnostics, Inc., will present new data demonstrating its ability to accurately detect liver cancer in high risk and average risk individuals at The Liver Meeting 2022, the annual meeting of the American Association for the Study of Liver Disease.
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022

Liver cancer is the sixth leading cancer killer in the United States and the third-leading cause of cancer-related deaths world wide. Globally, the high-risk population of over 350 million individuals is growing due to increases in fatty liver disease, cirrhosis, and chronic viral hepatitis infections. Meanwhile, screening rates remain below 20 percent in the U.S. and worldwide, despite longstanding recommendations for screening high-risk patients.

Researchers will present preliminary findings showing its platform can accurately and cost-effectively distinguish patients with hepatocellular carcinoma (HCC) from individuals without cancer, even when they suffer from other comorbidities.

"Liver cancer is the fastest growing cancer killer and is projected to become the third leading cause of cancer deaths in the U.S. by 2035. This is an exciting demonstration of the potential for Delfi's platform to address a growing public health problem," said Peter B. Bach, Delfi's Chief Medical Officer.

Oral Presentation Details:
Cell-free DNA fragmentomes for detection of liver cancer
Authors: Zachariah H. Foda, et. al
Session: Novel Approaches for Risk Stratification and Surveillance for HCC
Date: Monday, November 7, 2022
Time:  9:00 - 10:30 AM EST
About Delfi Diagnostics

Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi ("DNA Evaluation of Fragments for early Interception") is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.

SOURCE Delfi Diagnostics